Accelerate Your Viral Vector Manufacturing

A Complete, Ready-to-Use Viral Vector Platform

The exoREADY™ viral vector platform integrates high-performance starting materials—including proprietary cell lines and vector systems—with our data-driven expertise and comprehensive CMC documentation package. This package includes standard operating procedures, testing specifications, and material guidelines. Our flexible manufacturing technology, combined with regulatory support, offers a seamless solution for viral vector-based vaccines, oncolytic therapies, and gene therapy products.

Why Choose exoREADY?

Optimized for Industrial Manufacturing

  • ETailored for large-scale Cell and Gene Therapy (CGT) and Vaccine production.

Fully Customizable

  • EAdaptable to specific process requirements, ensuring flexibility and efficiency.

Regulatory & CMC Support

  • EStreamlined compliance with industry standards for a faster clinical transition.

Fast-Track Your Development Without Compromising Quality

Our mission is to reduce development timelines while maintaining the highest quality and cost efficiency.

Viral vectors technology platform and evolution exoready clinical phase timeline comparison

Advanced Manufacturing Processes

Developed for both adherent and suspension cell culture and equipped with the latest DSP technologies.

Suspension-Based Scalable Process

  • Scalability: Manufacturing scales at 40L, 200L, and 2000L in Stirred Tank Bioreactors.
  • Proven Agility & Robustness: Seamless scalability from process development to commercial production.
  • Effortless Tech Transfer: Simplified process transfer to your facility.
  • Advanced Process Control:
    • Scale-down models for process characterization and optimization.
    • Continuous processing/perfusion with ATF system.
    • Fully compatible with serum-free and chemically defined media.

Let’s discuss how exoREADY™ can streamline your manufacturing process. 

Adherent-Based Scalable Process

  • Scalability: Manufacturing scales at 10m², 30m², 200m², and 600m² in Fixed-Bed Bioreactors (scale-X™).
  • High Cell Density & Efficient Transfer: Optimized for adherent and suspension cell lines, ensuring a fast and monitored transition from flatware to GMP production.
  • Built-in Process Optimization:
    • Fixed-bed architecture acts as a pre-filter, simplifying perfusion management.
    • Integrated in-line clarification and TFF for streamlined purification.

Let’s discuss how exoREADY™ can streamline your manufacturing process. 

Unlock the Power of exoREADY™

Take advantage of our cutting-edge viral vector manufacturing technology to accelerate your pathway to clinical trials.